BR112014014239A2 - método, método para produzir um anticorpo, vetor de expressão, método para seleção de uma célula de mamífero recombinante, uso de um vetor de expressão, plasmídeo de expressão, um aspecto, método para a seleção de célula eucarionte que expressa um anticorpo, plasmídeo de expressão, uso de um plasmídeo de expressão e plasmídeo de expressão ou o uso ou o método - Google Patents

método, método para produzir um anticorpo, vetor de expressão, método para seleção de uma célula de mamífero recombinante, uso de um vetor de expressão, plasmídeo de expressão, um aspecto, método para a seleção de célula eucarionte que expressa um anticorpo, plasmídeo de expressão, uso de um plasmídeo de expressão e plasmídeo de expressão ou o uso ou o método

Info

Publication number
BR112014014239A2
BR112014014239A2 BR112014014239A BR112014014239A BR112014014239A2 BR 112014014239 A2 BR112014014239 A2 BR 112014014239A2 BR 112014014239 A BR112014014239 A BR 112014014239A BR 112014014239 A BR112014014239 A BR 112014014239A BR 112014014239 A2 BR112014014239 A2 BR 112014014239A2
Authority
BR
Brazil
Prior art keywords
expression
expression plasmid
antibody
selecting
plasmid
Prior art date
Application number
BR112014014239A
Other languages
English (en)
Other versions
BR112014014239B1 (pt
Inventor
Knoetgen Hendrik
Michael Huelsmann Peter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112014014239A2 publication Critical patent/BR112014014239A2/pt
Publication of BR112014014239B1 publication Critical patent/BR112014014239B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112014014239-4A 2011-12-22 2012-12-19 Método para selecionar uma célula recombinante de mamífero transfectada estável, método para produzir um anticorpo e vetor de expressão BR112014014239B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11195361.8 2011-12-22
EP11195361 2011-12-22
PCT/EP2012/076203 WO2013092743A2 (en) 2011-12-22 2012-12-19 Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Publications (2)

Publication Number Publication Date
BR112014014239A2 true BR112014014239A2 (pt) 2017-12-26
BR112014014239B1 BR112014014239B1 (pt) 2021-10-13

Family

ID=47504950

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014239-4A BR112014014239B1 (pt) 2011-12-22 2012-12-19 Método para selecionar uma célula recombinante de mamífero transfectada estável, método para produzir um anticorpo e vetor de expressão

Country Status (15)

Country Link
US (2) US20160208284A1 (pt)
EP (2) EP3354660A1 (pt)
JP (4) JP6096802B2 (pt)
KR (4) KR102166824B1 (pt)
CN (4) CN107119073A (pt)
BR (1) BR112014014239B1 (pt)
CA (2) CA2854249C (pt)
ES (1) ES2930215T3 (pt)
HK (1) HK1200848A1 (pt)
HR (1) HRP20221383T1 (pt)
MX (2) MX370481B (pt)
PL (1) PL2794651T3 (pt)
RU (2) RU2639519C2 (pt)
SG (3) SG10201700169PA (pt)
WO (1) WO2013092743A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2854249C (en) * 2011-12-22 2022-05-03 F. Hoffmann-La Roche Ag Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
BR112016007547A2 (pt) * 2013-10-07 2018-01-23 Prestige Biopharma Pte. Ltd. ?vetor de expressão bicistrônico para expressão de anticorpos e método para a produção de anticorpos usando o mesmo?
CN105255867A (zh) * 2015-10-19 2016-01-20 北京益生合生物科技有限公司 一种防止启动子在传代培养中逐渐灭活的基因序列及其应用
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
US11219695B2 (en) 2016-10-20 2022-01-11 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of Fabry disease
EP3624847A1 (en) * 2017-05-19 2020-03-25 Council of Scientific and Industrial Research A method for producing refolded recombinant humanized ranibizumab
JP7081139B2 (ja) * 2017-12-20 2022-06-07 東ソー株式会社 新規プロモーターおよびそれを含む発現ベクター
CN113015801A (zh) * 2018-09-20 2021-06-22 赛诺菲 基于内含子的通用克隆方法和组合物
JP7208380B2 (ja) * 2018-10-26 2023-01-18 エフ．ホフマン－ラ ロシュ アーゲー リコンビナーゼ媒介性カセット交換を使用した多重特異性抗体スクリーニング法
CN117043194A (zh) 2021-01-29 2023-11-10 默沙东有限责任公司 程序性死亡受体1（pd-1）抗体的组合物以及获得所述组合物的方法
KR102640929B1 (ko) 2023-06-02 2024-02-27 (주) 멥스젠 미세생체조직시스템 형성 장치

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
JP3051411B2 (ja) 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
RU2201449C2 (ru) * 1994-10-14 2003-03-27 Сембайозис Дженетикс Инк. Слитый полипептид, способный к целенаправленному переносу к масляному телу, химерная днк-контрукция, экспрессирующая кассета
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
NZ517906A (en) 1999-10-04 2003-01-31 Medicago Inc Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
IL149809A0 (en) 1999-12-15 2002-11-10 Genentech Inc Shotgun scanning, a combinatorial method for mapping functional protein epitopes
DK2857516T3 (en) 2000-04-11 2017-08-07 Genentech Inc Multivalent antibodies and uses thereof
KR100408844B1 (ko) * 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
EP1308517A1 (en) * 2001-10-31 2003-05-07 Aventis Pharmacueticals Products Inc. Vectors for expressing multiple transgenes
WO2003048306A2 (en) * 2001-11-16 2003-06-12 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
WO2003085118A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
EP2301966A1 (en) 2002-12-16 2011-03-30 Genentech, Inc. Immunoglobulin variants and uses thereof
CN100383244C (zh) * 2003-01-07 2008-04-23 西福根有限公司 用于生产重组多克隆蛋白质的方法
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
LT2348051T (lt) 2003-11-05 2019-02-25 Roche Glycart Ag Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2357201B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
CN101001953B (zh) * 2004-06-17 2013-03-13 惠氏公司 具有三个完整转录单元的质粒和用于诱导hiv免疫反应的免疫原性组合物
TW200732472A (en) * 2005-10-21 2007-09-01 Hoffmann La Roche Method for the recombinant expression of a polypeptide
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AR060871A1 (es) 2006-05-09 2008-07-16 Genentech Inc Union de polipeptidos con supercontigos optimizados
US20080124760A1 (en) * 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US20100015627A1 (en) * 2006-12-22 2010-01-21 Vincent Beuger Selection method
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
KR20140001229A (ko) * 2007-03-30 2014-01-06 아보트 러보러터리즈 숙주 세포에서 재조합 단백질의 발현을 증강시키기 위한 재조합 발현 벡터 요소(ｒＥＶＥ)
EP1995309A1 (en) * 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
CN101688222B (zh) * 2007-06-29 2013-03-06 弗·哈夫曼-拉罗切有限公司 启动子
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
PL2329020T3 (pl) * 2008-08-28 2013-08-30 Novartis Ag Prezentacja izoform polipeptydu na powierzchni komórki poprzez nadczytywanie kodonu stop
GB0903207D0 (en) * 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
SG175004A1 (en) 2009-04-02 2011-11-28 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010115589A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
CA2854249C (en) * 2011-12-22 2022-05-03 F. Hoffmann-La Roche Ag Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Also Published As

Publication number Publication date
SG10201900915WA (en) 2019-03-28
KR20140106585A (ko) 2014-09-03
RU2756910C2 (ru) 2021-10-06
MX370481B (es) 2019-12-16
CN107119073A (zh) 2017-09-01
WO2013092743A3 (en) 2013-10-03
CA3149402A1 (en) 2013-06-27
WO2013092743A2 (en) 2013-06-27
MX355624B (es) 2018-04-25
CN104011075B (zh) 2017-06-06
EP2794651A2 (en) 2014-10-29
CN113896787A (zh) 2022-01-07
JP2017108753A (ja) 2017-06-22
JP6417436B2 (ja) 2018-11-07
KR102048556B1 (ko) 2019-11-26
SG11201403443WA (en) 2014-07-30
KR102229491B1 (ko) 2021-03-18
JP2015500656A (ja) 2015-01-08
RU2017140661A3 (pt) 2021-08-09
KR102285184B1 (ko) 2021-08-03
JP2020054372A (ja) 2020-04-09
KR20200032240A (ko) 2020-03-25
US20160208284A1 (en) 2016-07-21
JP7096806B2 (ja) 2022-07-06
CA2854249A1 (en) 2013-06-27
PL2794651T3 (pl) 2022-12-27
RU2639519C2 (ru) 2017-12-21
HRP20221383T1 (hr) 2023-01-06
JP6096802B2 (ja) 2017-03-15
EP3354660A1 (en) 2018-08-01
RU2017140661A (ru) 2019-02-12
CN113881702A (zh) 2022-01-04
US20210024952A1 (en) 2021-01-28
KR102166824B1 (ko) 2020-10-19
SG10201700169PA (en) 2017-02-27
CN104011075A (zh) 2014-08-27
EP2794651B1 (en) 2022-09-21
HK1200848A1 (en) 2015-08-14
RU2014129727A (ru) 2016-02-20
KR20190132702A (ko) 2019-11-28
KR20210031002A (ko) 2021-03-18
MX2014007359A (es) 2014-08-01
BR112014014239B1 (pt) 2021-10-13
CA2854249C (en) 2022-05-03
ES2930215T3 (es) 2022-12-07
JP2019030311A (ja) 2019-02-28

Similar Documents

Publication Publication Date Title
BR112014014239A2 (pt) método, método para produzir um anticorpo, vetor de expressão, método para seleção de uma célula de mamífero recombinante, uso de um vetor de expressão, plasmídeo de expressão, um aspecto, método para a seleção de célula eucarionte que expressa um anticorpo, plasmídeo de expressão, uso de um plasmídeo de expressão e plasmídeo de expressão ou o uso ou o método
BR112014012624A2 (pt) anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
BR112015007120A2 (pt) anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
BR112014004168A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
BR112015030946A2 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
CR20150437A (es) Construcciones de anticuerpos para cdh19 y cd3
BR112014006155A2 (pt) método para determinar a adequação de um agente tensoativo para uso em uma formação
BR112015002091A2 (pt) método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
BR112012024287A2 (pt) anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
CO6801649A2 (es) Polipeptidos anticuerpos que antagonizan cd40
BR112013010993A2 (pt) método para a seleção de lotes de componentes de cultura para serem usados na cultura de uma célula de mamífero que expressa uma proteína de interesse
BR112015010680A2 (pt) aparelho de sonda ultrassônica, e método de controle de um aparelho de sonda ultrassônica
BR112013033730A2 (pt) cultura de células de mamífero
BR112013018311A2 (pt) sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
CO7020864A2 (es) Polipéptidos de anticuerpos que antagonizan cd40 l
EP3054015A4 (en) Mammalian gene modification method using electroporation
AR088322A1 (es) Anticuerpos anti-htra1 y metodos de uso
BR112013008255A2 (pt) anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
BR112012020372A8 (pt) anticorpo que se liga ao csf-1r humano, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo recombinante
EP3059319A4 (en) Bicistronic expression vector for antibody expression and method for producing antibody using same
BR112014008152A2 (pt) método para produção de uma proteina de interesse cultivando uma linhagem celular eucariótica recombinante compreendendo uma construção de expressão compreendendo um promotor regulável e uma molécula de ácido nucleico que codifica uma poi sob o controle transcricional de tal promotor
HK1200849A1 (en) Full length antibody display system for eukaryotic cells and its use
AR079704A1 (es) Anticuerpos anti-bv8 y sus usos
DK3212660T3 (da) Pattedyrsceller som udtrykker cytomegalovirusantigener
BR112013018845A2 (pt) expressão de glicoproteínas de fusão viral solúveis em células de mamífero

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.